Compile Data Set for Download or QSAR
Report error Found 81 Enz. Inhib. hit(s) with all data for entry = 12698
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720762BDBM720762(5-chloro-3-[6-(3,3,5,5-tetramethylpiperazin-1-yl)-...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720761BDBM720761(3-[4-chloro-6-(3-piperidyl)-2-pyridyl]-5-isopropox...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720759BDBM720759(5-chloro-3-[3-chloro-6-[(3S,5R)-3,5-dimethylpipera...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720757BDBM720757(5-chloro-3-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720754BDBM720754(5-chloro-3-[6-[(3R,5S)-3,5-dimethylpiperazin-1-yl]...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720755BDBM720755(5-chloro-3-[4-chloro-6-[(3S,5R)-3,5-dimethylpipera...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720752BDBM720752(3-[4-chloro-6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720753BDBM720753(5-chloro-3-[6-[(3R,5S)-3,5-dimethylpiperazin-1-yl]...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720703BDBM720703(5-chloro-3-[6-[(3R)-3-piperidyl]-2-pyridyl]pyrazol...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720751BDBM720751(3-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-2-pyridy...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720716BDBM720716(N-methyl-3-[6-(3-piperidyl)-2-pyridyl]pyrazolo[1,5...)
Affinity DataIC50: 10nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720714BDBM720714(5-cyclopropyl-3-[6-(3-piperidyl)-2-pyridyl]pyrazol...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720776BDBM720776(N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyrazolo[1,5-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720713BDBM720713(3-[6-(3-piperidyl)-2-pyridyl]pyrazolo[1,5-a]pyridi...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720777BDBM720777(N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyrazolo[1,5-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720774BDBM720774(N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyrazolo[1,5-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720775BDBM720775(N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyrazolo[1,5-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720772BDBM720772(N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyrazolo[1,5-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720709BDBM720709(5-isopropoxy-3-[6-(3-piperidyl)-2-pyridyl]pyrazolo...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720773BDBM720773(2-cyano-N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyraz...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720718BDBM720718(3-(methylsulfonamido)-N-(3-(6-(piperidin-3-yl)pyri...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720717BDBM720717(N-ethyl-3-[6-(3-piperidyl)-2-pyridyl]pyrazolo[1,5-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720763BDBM720763(2-(methylsulfonyl)-N-(3-(6-(piperidin-3-yl)pyridin...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720760BDBM720760(5-chloro-3-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720758BDBM720758(3-[4-chloro-6-(3-piperidyl)-2-pyridyl]-N-methyl-py...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720706BDBM720706(3-[6-(3-piperidyl)-2-pyridyl]-5-(trifluoromethyl)p...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720770BDBM720770(3-cyano-N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyraz...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720707BDBM720707(5-methoxy-3-[6-(3-piperidyl)-2-pyridyl]pyrazolo[1,...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720771BDBM720771(4-cyano-N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyraz...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720704BDBM720704(5-bromo-3-[6-(3-piperidyl)-2-pyridyl]pyrazolo[1,5-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720768BDBM720768(N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyrazolo[1,5-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720705BDBM720705(5-methyl-3-[6-(3-piperidyl)-2-pyridyl]pyrazolo[1,5...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720769BDBM720769(N-(3-(6-(piperidin-3-yl)pyridin-2-yl)pyrazolo[1,5-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720766BDBM720766((S)-3-(6-(3-methylpiperazin-1-yl)pyridin-2-yl)pyra...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720767BDBM720767(5-chloro-3-(6-((3S,5R)-3,4,5-trimethylpiperazin-1-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720700BDBM720700(Tert-butyl 3-(6-(5-chloropyrazolo[1,5-a]pyridin-3-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720764BDBM720764(2-(methylsulfonamido)-N-(3-(6-(piperidin-3-yl)pyri...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720701BDBM720701(Rac-5-chloro-3-[6-(3-piperidyl)-2-pyridyl]pyrazolo...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720765BDBM720765((R)-3-(6-(3-methylpiperazin-1-yl)pyridin-2-yl)pyra...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720746BDBM720746(3-[6-[(3R,5R)-3,5-dimethylpiperazin-1-yl]-2-pyridy...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720747BDBM720747(3-[4-chloro-6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720745BDBM720745(3-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-2-pyridy...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720742BDBM720742(3-(6-(5-chloropyrazolo[1,5-a]pyridin-3-yl)pyridin-...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720740BDBM720740(5-chloro-3-(4-fluoro-6-piperazin-1-yl-2-pyridyl)py...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720750BDBM720750(3-[4-chloro-6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720748BDBM720748(3-[6-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-4-fluoro...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720749BDBM720749(3-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-2-pyridy...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720730BDBM720730(5-chloro-3-[4-chloro-6-(3-piperidyl)-2-pyridyl]pyr...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720731BDBM720731(5-chloro-3-[4-fluoro-6-(3-piperidyl)-2-pyridyl] py...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Neuro3 Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 720728BDBM720728(3-[3-fluoro-6-(3-piperidyl)-2-pyridyl]pyrazolo[1,5...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound of Formula (I) to inhibit LRRK2 kinase activity is measured using a LanthaScreen™ kinase activity assay. In general, in a L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
US Patent

Displayed 1 to 50 (of 81 total ) | Next | Last >>
Jump to: